Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

[Inhibitors of the androgen receptor N‑terminal domain : Therapies targeting the Achilles' heel of various androgen receptor molecules in advanced prostate cancer].

Hupe MC, Offermann A, Perabo F, Chandhasin C, Perner S, Merseburger AS, Cronauer MV.

Urologe A. 2018 Feb;57(2):148-154. doi: 10.1007/s00120-017-0541-y. Review. German.

PMID:
29147733
2.

Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.

Antonarakis ES, Chandhasin C, Osbourne E, Luo J, Sadar MD, Perabo F.

Oncologist. 2016 Dec;21(12):1427-1435. Epub 2016 Sep 14.

3.

Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors.

Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A, Sankhala K, Mita A, Elian K, Bouchard D, Sarantopoulos J.

Mol Cancer Ther. 2012 Feb;11(2):308-16. doi: 10.1158/1535-7163.MCT-11-0566. Epub 2011 Dec 27.

4.

Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.

Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin C, LoRusso P.

Clin Cancer Res. 2011 Sep 15;17(18):6052-60. doi: 10.1158/1078-0432.CCR-10-2979. Epub 2011 Jul 12.

5.

Distinctive receptor binding properties of the surface glycoprotein of a natural feline leukemia virus isolate with unusual disease spectrum.

Bolin LL, Chandhasin C, Lobelle-Rich PA, Albritton LM, Levy LS.

Retrovirology. 2011 May 13;8:35. doi: 10.1186/1742-4690-8-35.

6.

Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience.

Naing A, Stephen SK, Frenkel M, Chandhasin C, Hong DS, Lei X, Falchook G, Wheler JJ, Fu S, Kurzrock R.

Cancer. 2011 Nov 15;117(22):5142-50. doi: 10.1002/cncr.26164. Epub 2011 Apr 28.

7.

Farnesyltransferase inhibitors: where are we now?

Tsimberidou AM, Chandhasin C, Kurzrock R.

Expert Opin Investig Drugs. 2010 Dec;19(12):1569-80. doi: 10.1517/13543784.2010.535516. Epub 2010 Nov 18. Review.

PMID:
21083522
8.

Human T-cell leukemia virus type 1 tax attenuates the ATM-mediated cellular DNA damage response.

Chandhasin C, Ducu RI, Berkovich E, Kastan MB, Marriott SJ.

J Virol. 2008 Jul;82(14):6952-61. doi: 10.1128/JVI.02331-07. Epub 2008 Apr 23.

9.

Unique long terminal repeat and surface glycoprotein gene sequences of feline leukemia virus as determinants of disease outcome.

Chandhasin C, Coan PN, Pandrea I, Grant CK, Lobelle-Rich PA, Puetter A, Levy LS.

J Virol. 2005 May;79(9):5278-87.

10.
11.

Impact of transforming viruses on cellular mutagenesis, genome stability, and cellular transformation.

Gatza ML, Chandhasin C, Ducu RI, Marriott SJ.

Environ Mol Mutagen. 2005 Mar-Apr;45(2-3):304-25. Review.

PMID:
15645440
12.

Feline leukaemia virus LTR variation and disease association in a geographical and temporal cluster.

Chandhasin C, Lobelle-Rich P, Levy LS.

J Gen Virol. 2004 Oct;85(Pt 10):2937-42.

PMID:
15448356

Supplemental Content

Loading ...
Support Center